Assessing the therapeutic effects of DPP4 Inhibitors on TGF-β2-induced Lens Opacity

Area of Science:

• Ophthalmology
• Cell Biology
• Pharmacology

Background:

• Posterior capsular opacification (PCO) is a frequent complication after cataract surgery.
• PCO stems from lens epithelial cells (LECs) undergoing epithelial-mesenchymal transition (EMT), impacting vision.
• Current treatments for PCO often require invasive procedures.

Purpose of the Study:

• To investigate the efficacy of dipeptidyl peptidase-4 (DPP4) inhibitors in preventing TGF-β-induced EMT in LECs.
• To explore the potential of Sitagliptin, Saxagliptin, and Vildagliptin as therapeutic agents for PCO.
• To determine if DPP4 inhibitors can mitigate fibrotic changes and slow PCO progression.

Main Methods:

• Human LECs and mouse lenses were treated with DPP4 inhibitors before TGF-β2 exposure.
• Epithelial-mesenchymal transition (EMT) markers (fibronectin, vimentin, α-smooth muscle actin) were analyzed.
• Techniques included immunostaining, Western blotting, and RT-qPCR to assess marker expression and Smad2 phosphorylation.

Main Results:

• DPP4 inhibitors effectively attenuated TGF-β2-induced EMT markers in both cell and lens explant cultures.
• Inhibition of Smad2 phosphorylation was identified as the mechanism of action.
• Vildagliptin treatment notably reduced TGF-β2-induced lens opacity in explant models.

Conclusions:

• DPP4 inhibitors demonstrate potential in preventing PCO by inhibiting TGF-β-induced EMT.
• Vildagliptin shows particular promise as a non-invasive pharmacological treatment for PCO.
• Targeting TGF-β signaling pathways with DPP4 inhibitors offers a novel therapeutic strategy for PCO.